Cochrane · systematic review · CD010189
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults
Holtick, U, Albrecht, M, Chemnitz, JM, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 71.4%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
BMT compared to PBSCT for haematological malignancies
Population: participants with haematological malignancies
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality BMT vs PBSCT | HR 1.07 [0.91, 1.25] | 6 studies · 1330 participants | High |
Progress, relapse or death BMT vs PBSCT | HR 1.04 [0.89, 1.21] | 6 studies · 1225 participants | Moderate Downgraded: risk of bias |
Non relapse or transplant related mortality BMT vs PBSCT | HR 0.98 [0.76, 1.28] | 3 studies · 758 participants | High |
Extensive chronic GvHD BMT vs PBSCT | HR 0.69 [0.54, 0.9] | 4 studies · 765 participants | Moderate Downgraded: risk of bias |
Acute GvHD III to IV BMT vs PBSCT | HR 0.75 [0.55, 1.02] | 3 studies · 925 participants | Moderate Downgraded: risk of bias |
Chronic GvHD overall BMT vs PBSCT | HR 0.72 [0.61, 0.85] | 4 studies · 1121 participants | Moderate Downgraded: risk of bias |
Acute GvHD II to IV BMT vs PBSCT | HR 1.03 [0.89, 1.21] | 6 studies · 1330 participants | Moderate Downgraded: risk of bias |